Progyny, Inc. (NASDAQ:PGNY) Receives Average Recommendation of “Hold” from Analysts

Progyny, Inc. (NASDAQ:PGNY) has earned a consensus rating of “Hold” from the thirteen analysts that are covering the firm, MarketBeat.com reports. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $24.82.

PGNY has been the topic of a number of research reports. Canaccord Genuity Group upped their target price on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, February 28th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th.

Insider Activity at Progyny

In related news, Chairman David J. Schlanger purchased 150,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Anevski purchased 209,500 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Mackenzie Financial Corp lifted its stake in Progyny by 423.8% in the fourth quarter. Mackenzie Financial Corp now owns 117,387 shares of the company’s stock valued at $2,025,000 after buying an additional 94,978 shares in the last quarter. AWM Investment Company Inc. lifted its stake in Progyny by 540.0% in the fourth quarter. AWM Investment Company Inc. now owns 160,000 shares of the company’s stock valued at $2,760,000 after buying an additional 135,000 shares in the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Progyny by 85.5% in the fourth quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company’s stock valued at $20,665,000 after purchasing an additional 552,066 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Progyny by 83.8% in the fourth quarter. Two Sigma Advisers LP now owns 266,100 shares of the company’s stock valued at $4,590,000 after purchasing an additional 121,300 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Progyny by 15.9% in the fourth quarter. Two Sigma Investments LP now owns 657,276 shares of the company’s stock valued at $11,338,000 after purchasing an additional 90,197 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Up 2.4 %

Shares of NASDAQ:PGNY opened at $21.71 on Thursday. Progyny has a 12 month low of $13.39 and a 12 month high of $38.98. The company’s 50-day moving average price is $21.80 and its two-hundred day moving average price is $18.61. The firm has a market cap of $1.85 billion, a P/E ratio of 37.43, a P/E/G ratio of 2.39 and a beta of 1.41.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.